Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-12-11
2007-12-11
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S488000
Reexamination Certificate
active
10480623
ABSTRACT:
The present invention relates to benzoxazepine derivative having the general formula I, wherein X represents CO or SO2; R1, R2, R3and R4are independently selected from H, (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkyloxy(C1-4)alkyl, halogen, nitro, cyano, NR8R9, NR8COR10, and CONR8R9, R5, R6and R7are independently H or (C1-4)alkyl; R8and R9are independently H or (C1-4)alkyl; or R8and R9form together with the nitrogen atom to which they are bound a 5- or 6-membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O, S or NR11; R10is (C1-4)alkyl; R11is (C1-4)alkyl; A represents the residue of a 4-7 membered saturated heterocyclic ring, optionally containing an oxygen atom, the ring being optionally substituted with 1-3 substituents selected from (C1-4)alkyl, (C1-4)alkyloxy, hydroxy, halogen and oxo; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said derivatives, and to the use of these benzoxazepine derivatives in the treatment of neurological diseases and psychiatric disorders which are responsive to enhancement of synaptic responses mediated by AMPA receptors in the central nervous system
REFERENCES:
patent: 6174881 (2001-01-01), Borer et al.
patent: 19 54 839 (1970-05-01), None
patent: 884 310 (1998-12-01), None
patent: 1238719 (1971-07-01), None
patent: WO 94/02475 (1994-02-01), None
patent: WO96/20941 (1996-07-01), None
patent: 96 38414 (1996-12-01), None
patent: 97 36907 (1997-10-01), None
patent: 99 33469 (1999-07-01), None
patent: 99 42456 (1999-08-01), None
patent: WO 99/51240 (1999-10-01), None
Schultz A G et al: “Enantioselective Method for Reductive Alkylation of Aromatic Carboxylic Acid Derivatives. Examination of the Factors that Provide Stereoselectivity”; Journal of the American Chemical Society, American Chemical Society, Washington, DC , vol. 110, No. 23, 1988, pp. 7828-7841.
Alterman et al., “Fast Microwave-Assisted Preparation of Aryl and Vinyl Nitriles and the Corresponding Tetrazoles from Organo-halides,”J. Org. Chem. 65(2000) 7984-7989.
Andrews et. al., “Effects of imipramine and mirtazapine on operant performance in rats,”Drug Dev. Res. 32(1994) 58-66.
Barn et.al., “Synthesis of Novel Analogues of the Delta Opioid Ligand SNC-80 Using AICI3-Promoted Aminolysis,”Biorg. Med. Chem. Lett. 9(1999)1329-34.
Bigge et al., “AMPA Receptor Agonists, Antagonists and Modulators: Their Potential for Clinical Utility,”Exp. Opin. Ther. Patents 7(1997) 1099-1114.
Brown et. al., “Selective Reductions. 30. Effect of Cation and Solvent on the Reactivity of Saline Borohydrides for Reduction of Carboxylic Esters, Improved Procedures for the Conversion of Esters to Alcohols by Metal Borohydrides,”J. Org. Chem. 47(1982) 4702-4708.
Grove et.al., “Positive Modulators of the AMPA Receptor,”Exp. Opin. Ther. Patents 10(2000) 1539-1548.
Hamill et. al., “Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches,”Pflügers Arch. 391(1981) 85-100.
Ireland et al., “Application of the Swern Oxidation to the Manipulation of Highly Reactive Carbonyl Compounds,”J. Org. Chem. 50(1985) 2198-2200.
Ito et al., “Allosteric Potentiation of Quisqualate Receptors by a Nootropic Drug Aniracetam,”J. Physiol. 424(1990) 533-543.
Krapcho, A.P., et. al. “Synthesis of Regioisomeric 6,9-(chlorofluoro)-Substituted Benzo[g]quinoline-5,10-diones, Benzo[g]isoquinoline-5,10-diones and 6-Chloro-9-fluorobenzo[g]quinoxaline-5,10-dione,”J. Het. Chem. 34(1997) 27-31.
Lees, G.J., “Pharmacology of AMPA/Kainate Receptor Ligands and Their Therapeutic Potential in Neurological and Psychiatric Disorders,”Drugs 59(2000) 33-78.
Mitsunobu, O., “The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products,”Synthesis 1(1981), 1-28.
Pasquier et al., “Free and Cr(CO)3-Complexed Aminophosphine Phosphinite Ligands for Highly Enantioselective Hydrogenation of α-functionalized Ketones,”Organometallics 19(2000) 5723-5732.
Reed et. al. “Structure—Activity Relationships of Cytotoxic Cholesterol-Modified DNA Duplexes,”J. Med Chem. 38(1995) 4587-4596.
Schoenberg A. et. al. “Palladium-Catalyzed Carboalkoxylation of Aryl, Benzyl, and Vinylic Halides,”J. Org. Chem. 39(1974) 3318-3326.
Schoenberg et al., “Palladium-Catalyzed Amidation of Aryl, Heterocyclic, and Vinylic Halides,”J. Org. Chem. 39(1974) 3327-3331.
Schultz et. al., “Regio- and Stereoselective Control in the Addition of Grignard Reagents to the Pyridine Ring System,”J. Org. Chem. 51(1986) 838-841.
Sleevi et al., “Optical Isomers of Rocastine and Close Analogues: Synthesis and H1 Antihistaminic Activity of Its Enantiomers and Their Structural Relationship to the Classical Antihistamines,”J. Med. Chem. 34(1991) 1314-1328.
Thurston et.al., “Synthesis and Reactivity of a Novel Oxazolo[2,3-c][1,4]benzodiazepine Ring System with DNA Recognition Potential: a New Class of Anthramycins,” J. Chem. Soc., Chem. Commun. (1990) 874-876.
Wolfe J.P. et. al. “Simple, Efficient Catalyst System for the Palladium-Catalyzed Amination of Aryl Chlorides, Bromides, and Triflates,”J. Org. Chem. 65(2000) 1158-1174.
Yamada et al., “Diazoxide Blocks Glutamate Desensitization and Prolongs Excitatory Postsynaptic Currents in Rat Hippocampal Neurons,”J. Physiol 458(1992) 409-423.
Yamada, K.A., “Therapeutic Potential of Positive AMPA Receptor Modulators in the Treatment of Neurological Disease,”Exp. Opin. Invest. Drugs 9(2000) 765-778.
Grove Simon James Anthony
Shahid Mohammad
Zhang Mingqiang
Hess Susan
Kifle Bruck
N.V. Organon
LandOfFree
Benzoxazepines derivatives and their use as AMPA receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzoxazepines derivatives and their use as AMPA receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzoxazepines derivatives and their use as AMPA receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3842276